SCHEMBL1485686

SCHEMBL1485686

CCNC1CCCCCCC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
KCNH2 Q12809 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 1/20 0.45
SHBG P04278 1/20 0.42
DPP7 Q9UHL4 2/20 0.41
HRH3 Q9Y5N1 1/20 0.41
EPHX1 P07099 2/20 0.40
PABPC1 P11940 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22416728 1.00 KDM4E (0.48) KDM4EKCNH2ALDH1A1HSD17B10SHBG
SCHEMBL22790769 1.00 KDM4E (0.48) KDM4EKCNH2ALDH1A1HSD17B10SHBG
SCHEMBL1037554 1.00 KDM4E (0.48) KDM4EKCNH2ALDH1A1HSD17B10SHBG
SCHEMBL24728 1.00
SCHEMBL11573949 1.00 KDM4E (0.48) KDM4EKCNH2ALDH1A1HSD17B10SHBG
SCHEMBL22316957 1.00 KDM4E (0.48) KDM4EKCNH2ALDH1A1HSD17B10SHBG
SCHEMBL17041905 0.97 KDM4E (0.46) KDM4EKCNH2ALDH1A1HSD17B10SHBG
Fluoride SCHEMBL9620604 0.97 KDM4E (0.46) KDM4EKCNH2ALDH1A1HSD17B10SHBG
Ammonia Solution, Strong SCHEMBL28857856 0.97 KDM4E (0.46) KDM4EKCNH2ALDH1A1HSD17B10SHBG
Bromide SCHEMBL28155616 0.97 KDM4E (0.46) KDM4EKCNH2ALDH1A1HSD17B10SHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143322-A1 USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) 2010-06-10 US claimed
EP-4694606-A1 RADIO WAVE SHIELDING BODY AND ADHESIVE COMPOSITION Zeon Corporation (JP) 2026-02-11 EP disclosed
WO-2024204796-A1 RADIO WAVE SHIELDING BODY AND ADHESIVE COMPOSITION 日本ゼオン株式会社 2024-10-03 WO disclosed
EP-4107198-B1 POLYISOCYANATE PREPARATIONS COVESTRO DEUTSCHLAND AG (DE) 2024-03-13 EP disclosed
US-11912714-B2 Spiropyrrolidine derived antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2024-02-27 US disclosed
EP-3560975-B2 IONICALLY HYDROPHILIZED POLYISOCYANATES AND ANTIOXIDANTS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-12-06 EP disclosed
EP-3724251-B2 IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-11-22 EP disclosed
WO-2023178378-A1 MIP INHIBITORS DMTC Limited (AU) 2023-09-28 WO disclosed
EP-3851472-B1 IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-06-07 EP disclosed
US-20230151019-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2023-05-18 US disclosed
EP-0838508-B1 Aqueous ink composition for use in an ink-jet printer SEIKO EPSON CORP (JP) 2001-08-29 EP disclosed
WO-2001047635-A2 SUPPORTED CATALYST SYSTEM CONTAINING A METALLOCENE, A LEWIS BASE AND AN ELEMENTALLY ORGANIC COMPOUND OF MAIN GROUP III AND THE USE THEREOF BASELL POLYPROPYLEN GMBH (DE) 2001-07-05 WO disclosed
US-5871572-A COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID SEIKO EPSON CORPORATION (JP) 1999-02-16 US disclosed
EP-0838508-A2 Aqueous ink composition for use in an ink-jet printer SEIKO EPSON CORPORATION (JP) 1998-04-29 EP disclosed
EP-0206621-B1 PROCESS FOR DISPROPORTIONATING SILANES MITSUI TOATSU CHEMICALS, Inc. (JP) 1989-11-15 EP disclosed
EP-0206621-A1 Process for disproportionating silanes MITSUI TOATSU CHEMICALS, Inc. (JP) 1986-12-30 EP disclosed
EP-0031284-B1 COMPOSITION AND METHOD FOR INHIBITING THE FORMATION OF NITROSAMINE IN ORGANIC AMINES BY ADDITION OF 1,4-NAPHTHOQUINONE, 1,4-NAPHTHOHYDROQUINONE OR ALKYL DERIVATIVES THEREOF UNION CARBIDE CORPORATION (US) 1984-02-01 EP disclosed
US-4273937-A Organic amine compositions UNION CARBIDE CORPORATION (US) 1981-06-16 US disclosed
US-4169896-A CONTROL OF COCCIDIAL DISEASES BY TREATMENT OF ANIMAL EXCRETA WITH SECONDARY AMINES CIBA-GEIGY CORPORATION (US) 1979-10-02 US disclosed
US-4112231-A Process for the condensation of epoxides with organic compounds having an active hydrogen BEROL KEMI AB (SE) 1978-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151019-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, PKD1 KDM4E 2622/4885KCNH2 738/4885ALDH1A1 386/4885
US-11912714-B2 Spiropyrrolidine derived antiviral agents ACE, ACE2, PKD1 KDM4E 2624/4885KCNH2 542/4885ALDH1A1 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.